If you are on medication for osteoporosis, are you ever tempted to stop taking it? If your answer is yes, you are not alone. Studies indicate that especially for those […]

UNBREAKABLE The OC Podcast : Bone Health + Osteoporosis UNBREAKABLE The OC Podcast from Osteoporosis Canada features evidence-based information from healthcare providers and subject matter experts, as well as personal […]

We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

Privacy Policy Our Commitment Osteoporosis Canada is committed to protecting the privacy of the personal information of its members, customers and other stakeholders. We value the trust of those we deal […]

Osteoporosis Canada’s Quality Standards for Fracture Liaison Services in Canada were developed to support implementation of effective FLS. They provide clear guidance for healthcare professionals and administrators on what an effective FLS […]

The recent study by Bolland and colleagues published in the Lancet Diabetes Endocrinology (Oct 4, 2018) is an updated meta-analysis that evaluated the effects of vitamin D supplementation on fractures, […]

  Our Financials YEAR ENDED MARCH 31, 2022 Osteoporosis Canada’s Program Fund, which accounts for revenue and expenses related to education, advocacy and awareness, administration, and fundraising, had a year-end […]

This report provides a national overview on diagnosed osteoporosis, related fractures and the osteoporosis care gap among Canadians 40 years and older.  It reports on administrative data from the Canadian […]